CCR5 Monoclonal Antibody CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Resistant to Maraviroc, a Small Molecule CCR5 AntagonistMolecule CCR5 Antagonist
CCR5 Monoclonal Antibody CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Resistant to Maraviroc, a Small Molecule CCR5 AntagonistMolecule CCR5 Antagonist
Andre J Marozsan
Progenics Pharmaceuticals, Inc.
IAS 2008
2
PRO 140 BackgroundPRO 140 Background
Humanized CCR5 monoclonal antibody
Broadly and potently inhibits CCR5-mediated HIV-1 entry in vitro
Distinct class of CCR5 inhibitor
– Binds extracellular domains vs. transmembrane pocket
• Inhibits HIV without blocking the natural activity of CCR5 in vitro
– Inhibits HIV via competitive vs. allosteric mechanism– Synergistic with small-molecule CCR5 antagonists– Potential for improved tolerability without drug-drug or
drug-food interactions– Potential for infrequent dosing
IAS 2008
3
0 1 0 2 0 3 0 4 0 5 0 6 0
Stu d y Da y
-2 .0
-1 .5
-1 .0
-0 .5
0 .0
0 .5
Me
an
Lo
g1
0 C
ha
ng
e i
n H
IV-1
RN
A
P la c e b o 0 .5 m g /k g 2 m g /k g 5 m g /k g
+++
+++
+++
+++
+++
+++
+++++
+ p ≤ 0.01++ p ≤ 0.001
+++ p ≤ 0.0001
PRO 140 Background (2)PRO 140 Background (2)
Potent, rapid, prolonged, dose-dependent antiviral activity in HIV-infected individuals
– 1.8 log10 mean reduction in HIV RNA following single 5 mg/kg IV dose
– >1.0 log10 mean reduction in HIV RNA for 2-3 weeks post-treatment
– Individual reductions up to 2.5 log10
Generally well tolerated
Designated FDA Fast Track drug candidate
IAS 2008
4
History of Case C Primary IsolatesHistory of Case C Primary Isolates
DateCD4
cells/mm3
MT2phenotype
Replication in HOS.CD4 cells[p24] (pg/ml)
CCR2 CCR3 CCR5 CXCR4
5/84 1,233 NSI <30 <30 1,024 <30
1/85 1,038 NSI <30 <30 72,400 <30
2/86 1,049 SI <30 <30 84,800 1,666
7/86 485 SI <30 <30 60,200 65,600
12/86 346 SI 16,240 12,700 31,000 43,100
5/87 141 SI 1,200 1,586 28,800 54,800
6/88 186 SI <30 <30 30,300 19,460
11/89 38 SI 6,600 11,240 31,200 24,000Conner et al. 1997. J. Exp. Med. 185:621-628.•Subtype B isolate
•Patient switched to X4 phenotype•Used as parental virus for AD101, vicriviroc and maraviroc escape studies
IAS 2008
5
Generation of Resistance: MethodsGeneration of Resistance: Methods
Culture for generation of resistance: Infect pooled donor PBMC with CC1.85 virus and culture in the presence
and absence of maraviroc. Begin escape cultures with drug concentration at the IC90. Passage cultures each week and monitor p24 production. Double inhibitor concentrations if p24 levels are stable in the culture. Cultures are considered resistant when viral replication is stable at the
highest concentration of drug for two weeks. Collect viral supernatants after 48 hours of drug-free growth.Generation of HIV-1 envelope clones and testing: Viral supernatants were analyzed at Monogram Biosciences (South San
Francisco, CA) using TrofileTM and PhenosenseTM Entry assays, as well as sequencing of the viral swarm.
Clonal analysis is in progress.
IAS 2008
6
Generation of Maraviroc- Resistant VirusGeneration of Maraviroc- Resistant Virus
0
0.5
1
1.5
2
2.5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Week
p2
4 G
row
th (
ng
/ml)
1
10
100
1000
10000
[ma
rav
iro
c]
nM
CC1.85 MVC EscapeCC1.85 PC[maraviroc] nM
Escape cultureIsolated atWeek 31
Passage controls isolated at Weeks 27 and 36
IAS 2008
7
Tropism AnalysisTropism Analysis
Passage Control Virus was R5-tropic at week 27
TrofileTM Analysis of Viral Swarm
100
1000
10000
100000
1000000
R5-RLU X4-RLU
U87.CD4.Coreceptor
RL
U
CC1.85 Parental
CC1.85 Passage Control wk 36
CC1.85 MVC Escape
IAS 2008
8
Maraviroc ResistanceMaraviroc Resistance
CC1.85 CC1.85 Passage Controlwk 27
CC1.85 MVC Escape
IC50 10 nM 11 nM not applicable
MPI 99% 100% 48%
PhenosenseTM Entry Assay Results
IAS 2008
9
PRO 140 SensitivityPRO 140 Sensitivity
CC1.85 CC1.85 MVC Escape
IC50 0.44 ug/mL 0.32 ug/mL 0.49 ug/mL
2.9 nM 2.1 nM 3.3 nM
MPI 98% 93% 98%
PhenosenseTM Entry Assay Results
CC1.85 Passage Controlwk 27
IAS 2008
10
Case C 1.85 SequencesCase C 1.85 Sequences
300 ^^^ CTRPNNNTRKSIHIGPGRAFYATGDIIGDIRQAHC......Y......M.....W.................................T..S...V...........................T..S...V.........
CC1.85 Parental IsolateCC1.85 Passage ControlCC1.85 MVC Escape
R5
R5DM
V1/V2 - a two amino acid deletion at positions 188-189 was observed in the maraviroc escape virus and in the passage control virus. This deletion was observed in prior Case C escape cultures and was associated with increased CD4 dependence (Pugach et al. Virology. 321:8-22. 2004).
V3 Region
R5CC1.85 MVC Escape(Pfizer*)
*Westby et al. 2007. J. Virol. 81:2359-2371
IAS 2008
11
Summary of Viral CharacteristicsSummary of Viral Characteristics
Virus Tropism Inhibitor IC50 MPI
CC 1.85 ParentalR5 PRO 140
0.44 ug/mL2.9 nM
98
Maraviroc 10 nM 99
CC 1.85 MVC EscapeWk 31
R5 PRO 1400.49 ug/mL
3.3 nM98
Maraviroc >6 uM 48
CC 1.85 Passage ControlWk 27
R5 PRO 1400.32 ug/mL
2.1 nM93
Maraviroc 11 nM 100
CC 1.85 Passage ControlWk 36
DM PRO 140 NA NA
Maraviroc NA NA
IAS 2008
12
SummarySummary
A virus resistant to maraviroc was generated in PBMC culture over 31 weeks of passage.
The maraviroc escape virus remained R5; however, the passage control virus became R5X4.
The maraviroc escape virus displayed similar phenotype and sequence to one generated by Pfizer.
For Case C 1/85, maraviroc resistance did not confer cross-resistance to PRO 140.
IAS 2008
13
AcknowledgmentsAcknowledgments
Progenics Pharmaceuticals, Inc.
• Tom Ketas• William Olson, Ph.D.• Paul Maddon, M.D., Ph.D.
Monogram Biosciences, Inc.
• Wei Huang, Ph.D.• Jonathan Toma, Ph.D.• Jeannette Whitcomb, Ph.D.• Chris Petropoulos, Ph.D.
This study was supported byPublic Health Service awardAI066329 from the National
Institute of Allergy and Infectious Diseases